Literature DB >> 27628691

An Ultra-High-Throughput Screen for Catalytic Inhibitors of Serine/Threonine Protein Phosphatases Types 1 and 5 (PP1C and PP5C).

Mark Swingle1, Claude-Henry Volmar2,3, S Adrian Saldanha2,4, Peter Chase2,5, Christina Eberhart2, Edward A Salter1, Brandon D'Arcy1, Chad E Schroeder6, Jennifer E Golden6, Andrzej Wierzbicki1, Peter Hodder2,7, Richard E Honkanen1.   

Abstract

Although there has been substantial success in the development of specific inhibitors for protein kinases, little progress has been made in the identification of specific inhibitors for their protein phosphatase counterparts. Inhibitors of PP1 and PP5 are desired as probes for research and to test their potential for drug development. We developed and miniaturized (1536-well plate format) nearly identical homogeneous, fluorescence intensity (FLINT) enzymatic assays to detect inhibitors of PP1 or PP5. The assays were used in an ultra-high-throughput screening (uHTS) campaign, testing >315,000 small-molecule compounds. Both assays demonstrated robust performance, with a Z' of 0.92 ± 0.03 and 0.95 ± 0.01 for the PP1 and PP5 assays, respectively. Screening the same library with both assays aided the identification of class inhibitors and assay artifacts. Confirmation screening and hit prioritization assays used [32P/33P]-radiolabel protein substrates, revealing excellent agreement between the FLINT and radiolabel assays. This screening campaign led to the discovery of four novel unrelated small-molecule inhibitors of PP1 and ~30 related small-molecule inhibitors of PP5. The results suggest that this uHTS approach is suitable for identifying selective chemical probes that inhibit PP1 or PP5 activity, and it is likely that similar assays can be developed for other PPP-family phosphatases.

Entities:  

Keywords:  MLPCN; PP1C; PP5C; fluorescent assay; inhibitors; phosphatase

Mesh:

Substances:

Year:  2016        PMID: 27628691      PMCID: PMC8041090          DOI: 10.1177/1087057116668852

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  32 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Regulators of serine/threonine protein phosphatases at the dawn of a clinical era?

Authors:  R E Honkanen; T Golden
Journal:  Curr Med Chem       Date:  2002-11       Impact factor: 4.530

Review 3.  Protein phosphatases in pancreatic islets.

Authors:  Henrik Ortsäter; Nina Grankvist; Richard E Honkanen; Åke Sjöholm
Journal:  J Endocrinol       Date:  2014-03-28       Impact factor: 4.286

4.  Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse.

Authors:  Mark Swingle; Li Ni; Richard E Honkanen
Journal:  Methods Mol Biol       Date:  2007

5.  Calcineurin inhibitors: 40 years later, can't live without ...

Authors:  Jamil R Azzi; Mohamed H Sayegh; Samir G Mallat
Journal:  J Immunol       Date:  2013-12-15       Impact factor: 5.422

6.  Development and validation of a robust and sensitive assay for the discovery of selective inhibitors for serine/threonine protein phosphatases PP1α (PPP1C) and PP5 (PPP5C).

Authors:  Mark R Swingle; Richard E Honkanen
Journal:  Assay Drug Dev Technol       Date:  2014-10       Impact factor: 1.738

7.  Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer.

Authors:  Teresa Golden; Ileana V Aragon; Beth Rutland; J Allan Tucker; Lalita A Shevde; Rajeev S Samant; Guofei Zhou; Lauren Amable; Danalea Skarra; Richard E Honkanen
Journal:  Biochim Biophys Acta       Date:  2008-01-26

8.  Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A.

Authors:  R E Honkanen
Journal:  FEBS Lett       Date:  1993-09-20       Impact factor: 4.124

9.  Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression.

Authors:  Gudrun Urban; Teresa Golden; Ileana V Aragon; Lex Cowsert; Scott R Cooper; Nicholas M Dean; Richard E Honkanen
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

10.  Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C.

Authors:  Debasish Chattopadhyay; Mark R Swingle; Edward A Salter; Eric Wood; Brandon D'Arcy; Catherine Zivanov; Kevin Abney; Alla Musiyenko; Scott F Rusin; Arminja Kettenbach; Larry Yet; Chad E Schroeder; Jennifer E Golden; Wade H Dunham; Anne-Claude Gingras; Surajit Banerjee; David Forbes; Andrzej Wierzbicki; Richard E Honkanen
Journal:  Biochem Pharmacol       Date:  2016-03-23       Impact factor: 5.858

View more
  4 in total

1.  The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active-Site Catalytic Metals in PPP5C.

Authors:  Brandon M D'Arcy; Mark R Swingle; Cinta M Papke; Kevin A Abney; Erin S Bouska; Aishwarya Prakash; Richard E Honkanen
Journal:  Mol Cancer Ther       Date:  2019-01-24       Impact factor: 6.261

Review 2.  Structure and function of the co-chaperone protein phosphatase 5 in cancer.

Authors:  Rebecca A Sager; Natela Dushukyan; Mark Woodford; Mehdi Mollapour
Journal:  Cell Stress Chaperones       Date:  2020-04-02       Impact factor: 3.667

Review 3.  Miklós Bodanszky Award Lecture: Advances in the selective targeting of protein phosphatase-1 and phosphatase-2A with peptides.

Authors:  Maja Köhn
Journal:  J Pept Sci       Date:  2017-10       Impact factor: 1.905

4.  High-throughput metabolomics predicts drug-target relationships for eukaryotic proteins.

Authors:  Duncan Holbrook-Smith; Stephan Durot; Uwe Sauer
Journal:  Mol Syst Biol       Date:  2022-02       Impact factor: 11.429

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.